Adrenal cortex autoantibodies (ACAs) and/or 21-hydroxylase (21OHAb) are markers of autoimmune Addison’s disease (AAD) and progression to overt AAD. The reported cumulative risk of developing AAD varies from 0 to 90% in different studies.
To assess the predictive value of different parameters in the progression toward AAD in patients with ACA and/or 21OHAb-positive patients with autoimmune polyendocrine syndromes (APS).
Materials and methods
Twenty-nine patients with APS-1 and 114 patients with APS-2 or APS-4 were followed up for a median of 10 years (range 6 months to 33 years) and were assessed using ACTH test. The risk of AAD was estimated according to age, gender, stage of adrenal dysfunction, associated diseases and antibody titer. Univariate and multivariate Cox proportional hazard models were used for statistical analysis.
The cumulative risk (CR) of developing AAD was higher in APS-1 patients (94.2%) than in patients with APS-2/APS-4 (38.7%). The CR was high in both male and female APS-1 patients, while in patients with APS-2/APS-4 it was high only in males. Stage 1 (increased plasma renin) for patients with APS-1 and Stage 2 (no response of cortisol to ACTH test) for patients with APS-2/APS-4 were established as the points of no return in the progression to AAD. Adjusted hazard ratio analyses by multivariate Cox model for AAD showed that gender, diseases and adrenal function were independent risk factors for developing clinical AAD. The risk of developing clinical AAD appears to subside after 19 years of follow-up.
A model for estimating the probability to survive free of AAD has been developed and should be a useful tool in designing appropriate follow-up intervals and future therapeutic strategies.
BetterleCDal PraCManteroFZanchettaR.Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocrine Review200223327–364. (https://doi.org/10.1210/edrv.23.3.0466)
BetterleCScarpaRGarelliSMorlinLLazzarottoFPresottoFCocoGMasieroSParoloAAlbergoniMPet al. Addison’s disease: a survey on 633 patients in Padova. European Journal of Endocrinology2013169773–784. (https://doi.org/10.1530/EJE-13-0528)
OrlovaEMSozaevaLSKarevaMAOftedalBEWolffASBBreivikLZakharovaEYIvanovaONKämpeODedovIIet al. Expanding the phenotypic and genotypic landscape of autoimmune polyendocrine syndrome type 1. Journal of Clinical Endocrinology and Metabolism20171023546–3556. (https://doi.org/10.1210/jc.2017-00139)
BetterleCCocoGZanchettaR.Adrenal cortex autoantibodies in subjects with normal adrenal function. Best Practice and Research Clinical Endocrinology and Metabolism20051985–89. (https://doi.org/10.1016/j.beem.2004.11.008)
BetterleCVolpatoMRees SmithBFurmaniakJChenSZanchettaRGreggioNAPediniBBoscaroMPresottoF.II. Adrenal cortex and steroid 21-hydroxylase autoantibodies in children with organ-specific autoimmune diseases: markers of high progression to clinical Addison’s disease. Journal of Clinical Endocrinology and Metabolism199782939–942. (https://doi.org/10.1210/jcem.82.3.3849)
BetterleCVolpatoMRees SmithBFurmaniakJChenSGreggioNASanzariMTedescoFPediniBBoscaroMet al. I. Adrenal cortex and steroid 21-hydroxylase autoantibodies in adult patients with organ specific autoimmune diseases: markers of low progression to clinical Addison’s disease. Journal of Clinical Endocrinology and Metabolism199782932–938. (https://doi.org/10.1210/jcem.82.3.3819)
FalorniALauretiSNikoshkovAPicchioMLHallengrenBVandewalleCLGorusFKTortoioliCLuthmanHBrunettiPet al. 21-Hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison’s disease. Belgian Diabetes Registry. Clinical and Experimental Immunology1997107341–346. (https://doi.org/10.1111/j.1365-2249.1997.262-ce1153.x)
YuLBrewerKWGatesSWuAWangTBabuSRGottliebPAFreedBMNobleJErlichHAet al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison’s disease. Journal of Clinical Endocrinology and Metabolism199984328–335. (https://doi.org/10.1210/jcem.84.1.5414)
PetersonPSalmiHHyötyHMiettinenAIlonenJReijonenHKnipMAkerblomHKKrohnK.Steroid 21-hydroxylase autoantibodies in insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. Clinical Immunology and Immunopathology19978237–42. (https://doi.org/10.1006/clin.1996.4277)
BarkerJMIdeAHostetlerCYuLMiaoDFainPREisenbarthGSGottliebPA.Endocrine and immunogenetic testing in individuals with type 1 diabetes and 21-hydroxylase autoantibodies: Addison’s disease in a high-risk population. Journal of Clinical Endocrinology and Metabolism200590128–134. (https://doi.org/10.1210/jc.2004-0874)
BakerPRNanduriPGottliebPAYuLKlingensmithGJEisenbarthGSBarkerJM.Predicting the onset of Addison’s disease: ACTH, renin, cortisol and 21-hydroxylase autoantibodies. Clinical Endocrinology201276617–624. (https://doi.org/10.1111/j.1365-2265.2011.04276.x)
Del Pilar LarosaMChenSSteinmausNMacraeHGuoLMasieroSGarelliSDalla CostaMBossowskiAFurmaniakJet al. A new ELISA for autoantibodies to steroid 21-hydroxylase. Clinical Chemistry and Laboratory Medicine201856933–938. (https://doi.org/10.1515/cclm-2017-0456)
BetterleCZanetteFZanchettaRPediniBTrevisanAManteroFRigonF.Complement-fixing adrenal autoantibodies as a marker for predicting onset of idiopathic Addison’s disease. Lancet198311238–1241. (https://doi.org/10.1016/S0140-6736(83)92695-8)
AhonenPMiettinenAPerheentupaJ.Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease type I and risk of adrenocortical and ovarian failure. Journal of Clinical Endocrinology and Metabolism198764494–500. (https://doi.org/10.1210/jcem-64-3-494)
BetterleCScaliciCPresottoFPediniBMoroLRigonFManteroF.The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. Journal of Endocrinology1988117467–475. (https://doi.org/10.1677/joe.0.1170467)
LauretiSDe BellisAMMuccitelliVICalcinaroFBizzaroARossiRBellastellaASanteusanioFFalorniA.Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison’s disease. Journal of Clinical Endocrinology and Metabolism1998833507–3511. (https://doi.org/10.1210/jcem.83.10.5149)
CocoGDal PraCPresottoFAlbergoniMPCanovaCPediniBZanchettaRChenSFurmaniakJRees SmithBet al. Estimated risk for developing autoimmune Addison’s disease in patients with adrenal cortex autoantibodies. Journal of Clinical Endocrinology and Metabolism2006911637–1645. (https://doi.org/10.1210/jc.2005-0860)
BetterleCGarelliSPresottoFFurmaniakJ.From appearance of adrenal autoantibodies to clinical symptoms of Addison’s disease: natural history. Frontiers of Hormonal Research201646133–145. (https://doi.org/10.1159/000443872)
CervatoSMarinielloBLazzarottoFMorlinLZanchettaRRadettiGDe LucaFValenziseMGiordanoRRizzoDet al. Evaluation of these autoimmune regulator (AIRE) gene mutations in a cohort of Italian patients with autoimmune-polyendocrinopathy-candidiasis-ectodermal-dystrophy (APECED) and in their relatives. Clinical Endocrinology200970421–428. (https://doi.org/10.1111/j.1365-2265.2008.03318.x)
De BellisABizzarroARossiRPaglionicoVACriscuoloTLombardiGBellastellaA.Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. Journal of Clinical Endocrinology and Metabolism1993761002–1007. (https://doi.org/10.1210/jcem.76.4.8473373)
De BellisAMFalorniALauretiSPerrinoSCoronellaCForiniFBizzarroEBizzarroAAbbateGBellastellaA.Time course of 21-hydroxylase antibodies and long-term remission of subclinical autoimmune adrenalitis after corticosteroid therapy: case report. Journal of Clinical Endocrinology and Metabolism200186675–678. (https://doi.org/10.1210/jcem.86.2.7212)
MansoJPezzaniRScarpaRGalloNBetterleC.The natural history of autoimmune Addison’s disease with a non-classical presentation: a case report and review of literature. Clinical Chemistry and Laboratory Medicine201856896–900. (https://doi.org/10.1515/cclm-2017-1108)
GambelungheGFalorniAGhaderiMLauretiSTortoioliCSanteusanioFBrunettiPSanjeeviCB.Microsatellite polymorphism of the MHC class I chain-related (MIC-A and MIC-B) genes marks the risk for autoimmune Addison’s disease. Journal of Clinical Endocrinology and Metabolism1999843701–3707. (https://doi.org/10.1210/jcem.84.10.6069)